ZL-1102-002 Enrolling

Chronic Plaque Psoriasis – Research Trial (24 Weeks)


Treatment: Topical Age: 18+


Adults aged 18 years or older with a clinical diagnosis of psoriasis vulgaris of at least 6 months duration, are needed for this clinical trial. Individuals must have the disease affecting 3%-10% of the body surface area (BSA) (excluding head) to be eligible for topical treatment. Adults must not have other types of psoriasis dominant other than plaque psoriasis. During the study period, participants must also agree not to have prolonged sun exposure.

Participants will receive investigational topical treatment (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses will be provided.

Study participation will last about 24 weeks and involve about 8 visits to the study centre.


Participating Locations

COUNTRY
country-icon
Australia

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: July 16, 2024

Official Title

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

ClinicalTrials.gov ID

NCT06380907

Sponsor

Zai Lab (Hong Kong), Ltd.

Study Description

  • Brief Summary:

    A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

  • Condition or Disease:

    Plaque Psoriasis

  • Intervention/Treatment:

    Drug: ZL-1102 1% w/w gel BID for 16 weeks Drug: ZL-1102 3% w/w gel BID for 16 weeks Drug: ZL-1102 3% w/w gel QD for 16 weeks Drug: Placebo ZL-1102 0% w/w gel BID for 16 weeks Drug: Placebo ZL-1102 0% w/w gel QD for 16 weeks
  • Phase:

    PHASE2

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL

Adults aged 18 years or older with a clinical diagnosis of psoriasis vulgaris of at least 6 months duration, are needed for this clinical trial. Individuals must have the disease affecting 3%-10% of the body surface area (BSA) (excluding head) to be eligible for topical treatment. Adults must not have other types of psoriasis dominant other than plaque psoriasis. During the study period, participants must also agree not to have prolonged sun exposure.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Psoriasis

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content